Tuomela et al. BMC Cancer 2010, 10:596 http://www.biomedcentral.com/1471-2407/10/596 19. Suzuki M, Satoh A, Ide H, Tamura K: Nerve-dependent and -independent events in blastema formation during xenopus froglet limb regeneration. Dev Biol 2005, 286(1):361-75. 20. Valta MP, Tuomela J, Vuorikoski H, Loponen N, Väänänen RM, Pettersson K, Väänänen HK, Härkönen PL: FGF-8b induces growth and rich vascularization in an orthotopic PC-3 model of prostate cancer. J Cell Biochem 2009, 107(4):769-84. 21. Valta MP, Hentunen T, Qu Q, Valve EM, Harjula A, Seppänen JA, Väänänen HK, Härkönen PL: Regulation of osteoblast differentiation: A novel function for fibroblast growth factor 8. Endocrinology 2006, 147(5):2171-82. 22. Kwabi-Addo B, Ozen M, Ittmann M: The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer 2004, 11(4):709-24. 23. Mattila MM, Härkonen PL: Role of fibroblast growth factor 8 in growth and progression of hormonal cancer. Cytokine Growth Factor Rev 2007, 18(3-4):257-66. 24. Doll JA, Reiher FK, Crawford SE, Pins MR, Campbell SC, Bouck NP: Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate. Prostate 2001, 49(4):293-305. 25. Huss WJ, Barrios RJ, Foster BA, Greenberg NM: Differential expression of specific FGF ligand and receptor isoforms during angiogenesis associated with prostate cancer progression. Prostate 2003, 54(1):8-16. 26. Valve EM, Nevalainen MT, Nurmi MJ, Laato MK, Martikainen PM, Härkonen PL: Increased expression of FGF-8 isoforms and FGF receptors in human premalignant prostatic intraepithelial neoplasia lesions and prostate cancer. Lab Invest 2001, 81(6):815-26. 27. Heer R, Douglas D, Mathers ME, Robson CN, Leung HY: Fibroblast growth factor 17 is over-expressed in human prostate cancer. J Pathol 2004, 204(5):578-86. 28. Tanaka A, Miyamoto K, Minamino N, Takeda M, Sato B, Matsuo H, Matsumoto K: Cloning and characterization of an androgen-induced growth factor essential for the androgen-dependent growth of mouse mammary carcinoma cells. Proc Natl Acad Sci USA 1992, 89(19):8928-32. 29. Ghosh AK, Shankar DB, Shackleford GM, Wu K, T’Ang A, Miller GJ, Zheng J, Roy-Burman P: Molecular cloning and characterization of human FGF8 alternative messenger RNA forms. Cell Growth Differ 1996, 7(10):1425-34. 30. Song Z, Wu X, Powell WC, Cardiff RD, Cohen MB, Tin RT, Matusik RJ, Miller GJ, Roy-Burman P: Fibroblast growth factor 8 isoform B overexpression in prostate epithelium: A new mouse model for prostatic intraepithelial neoplasia. Cancer Res 2002, 62(17):5096-105. 31. Tanaka A, Furuya A, Yamasaki M, Hanai N, Kuriki K, Kamiakito T, Kobayashi Y, Yoshida H, Koike M, Fukayama M: High frequency of fibroblast growth factor (FGF) 8 expression in clinical prostate cancers and breast tissues, immunohistochemically demonstrated by a newly established neutralizing monoclonal antibody against FGF 8. Cancer Res 1998, 58(10):2053-6. 32. Dorkin TJ, Robinson MC, Marsh C, Bjartell A, Neal DE, Leung HY: FGF8 over- expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. Oncogene 1999, 18(17):2755-61. 33. Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F, Gao G, Goldfarb M: Receptor specificity of the fibroblast growth factor family. J Biol Chem 1996, 271(25):15292-7. 34. Ruohola JK, Viitanen TP, Valve EM, Seppänen JA, Loponen NT, Keskitalo JJ, Lakkakorpi PT, Härkönen PL: Enhanced invasion and tumor growth of fibroblast growth factor 8b-overexpressing MCF-7 human breast cancer cells. Cancer Res 2001, 61(10):4229-37. 35. Mattila MM, Ruohola JK, Valve EM, Tasanen MJ, Seppänen JA, Härkönen PL: FGF-8b increases angiogenic capacity and tumor growth of androgen- regulated S115 breast cancer cells. Oncogene 2001, 20(22):2791-804. 36. Song Z, Powell WC, Kasahara N, van Bokhoven A, Miller GJ, Roy-Burman P: The effect of fibroblast growth factor 8, isoform b, on the biology of prostate carcinoma cells and their interaction with stromal cells. Cancer Res 2000, 60(23):6730-6. 37. Rudra-Ganguly N, Zheng J, Hoang AT, Roy-Burman P: Downregulation of human FGF8 activity by antisense constructs in murine fibroblastic and human prostatic carcinoma cell systems. Oncogene 1998, 16(11):1487-92. Page 13 of 14 38. Valta MP, Tuomela J, Bjartell A, Valve E, Väänänen HK, Härkönen P: FGF-8 is involved in bone metastasis of prostate cancer. Int J Cancer 2008, 123(1):22-31. 39. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246(4935):1306-9. 40. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987, 162(1):156-9. 41. Ruohola JK, Valve EM, Vainikka S, Alitalo K, Härkönen PL: Androgen and fibroblast growth factor (FGF) regulation of FGF receptors in S115 mouse mammary tumor cells. Endocrinology 1995, 136(5):2179-88. 42. Ruohola JK, Valve EM, Kärkkäinen MJ, Joukov V, Alitalo K, Härkönen PL: Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells. Mol Cell Endocrinol 1999, 149(1-2):29-40. 43. Wärri AM, Huovinen RL, Laine AM, Martikainen PM, Härkönen PL: Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro. J Natl Cancer Inst 1993, 85(17):1412-8. 44. Tuomela JM, Valta MP, Väänänen K, Härkönen PL: Alendronate decreases orthotopic PC-3 prostate tumor growth and metastasis to prostate- draining lymph nodes in nude mice. BMC Cancer 2008, 8:81. 45. Bergman J, Solin O: Fluorine-18-labeled fluorine gas for synthesis of tracer molecules. Nucl Med Biol 1997, 24(7):677-83. 46. Evans SM, Judy KD, Dunphy I, Jenkins WT, Nelson PT, Collins R, Wileyto EP, Jenkins K, Hahn SM, Stewens CW, Judkins AR, Philips P, Geoerger B, Koch CJ: Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding. Cancer Res 2004, 64(5):1886-92. 47. Grönroos T, Bentzen L, Marjamäki P, Murata R, Horsman MR, Keiding S, Eskola O, Haaparanta M, Minn H, Solin O: Comparison of the biodistribution of two hypoxia markers [18F]FETNIM and [18F]FMISO in an experimental mammary carcinoma. Eur J Nucl Med Mol Imaging 2004, 31(4):513-20. 48. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ: Targeting of HIF-alpha to the von hippel-lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001, 292(5516):468-72. 49. Wang GL, Semenza GL: Purification and characterization of hypoxia- inducible factor 1. J Biol Chem 1995, 270(3):1230-7. 50. Siddiqui K, Klotz LH: Emerging drugs for prostate cancer. Expert Opin Emerg Drugs 2009, 14(3):455-70. 51. Minn H, Grönroos TJ, Komar G, Eskola O, Lehtiö K, Tuomela J, Seppänen M, Solin O: Imaging of tumor hypoxia to predict treatment sensitivity. Curr Pharm Des 2008, 14(28):2932-42. 52. Semenza GL, Artemov D, Bedi A, Bhujwalla Z, Chiles K, Feldser D, Laughner E, Ravi R, Simons J, Taghavi P, Zheng H: ’The metabolism of tumours’: 70 years later. Novartis Found Symp 2001, 240:251, 60; discussion 260-4. 53. Cao R, Brakenhielm E, Pawliuk R, Wariaro D, Post MJ, Wahlberg E, Leboulch P, Cao Y: Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med 2003, 9(5):604-13. 54. Sutherland RM, Ausserer WA, Murphy BJ, Laderoute KR: Tumor hypoxia and heterogeneity: Challenges and opportunities for the future. Semin Radiat Oncol 1996, 6(1):59-70. 55. Castell F, Cook GJ: Quantitative techniques in 18FDG PET scanning in oncology. Br J Cancer 2008, 98(10):1597-601. 56. Airley RE, Mobasheri A: Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: Novel pathways and targets for anticancer therapeutics. Chemotherapy 2007, 53(4):233-56. 57. Komar G, Seppänen M, Eskola O, Lindholm P, Grönroos TJ, Forsback S, Sipilä H, Evans SM, Solin O, Minn H: 18F-EF5: A new PET tracer for imaging hypoxia in head and neck cancer. J Nucl Med 2008, 49(12):1944-51. 58. Rajendran JG, Mankoff DA, O’Sullivan F, Peterson LM, Schwartz DL, Conrad EU, Spence AM, Muzi M, Farwell DG, Krohn KA: Hypoxia and glucose metabolism in malignant tumors: Evaluation by [18F] fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 2004, 10(7):2245-52.